Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis.

Chan, Sik-Kwan; Choi, Horace Cheuk-Wai; Lee, Victor Ho-Fun

Chan, Sik-Kwan; Choi, Horace Cheuk-Wai; Lee, Victor Ho-Fun.

Afiliação

Chan SK; Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Choi HC; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Lee VH; Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

JTO Clin Res Rep ; 3(5): 100322, 2022 May.

Article em En | MEDLINE | ID: mdl-35516725

Palavras-chave

Asian; Epidermal growth factor receptor; L858R mutation; Nonsmall-cell lung cancer; Tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google